Economists at the U.S. International Trade Commission (ITC) have recently released a comprehensive report on the global availability of COVID-19 treatments. While the report did not advocate for any particular stance, it did acknowledge the role of intellectual property constraints in the distribution of some coronavirus testing kits and other medical supplies.
The ITC, an independent federal agency that provides trade expertise to both the legislative and executive branches of the U.S. government, has been particularly instrumental in the current COVID-19 global crisis by analyzing key healthcare distribution channels and their related challenges. As stated in the report, one of these challenges is the impact of intellectual property rights on the distribution of crucial medical products.
The report underscored the influence of intellectual property protections in creating potential roadblocks in the delivery of much-needed medical supplies worldwide – from COVID-19 testing kits to other essential medical products. The existence of these roadblocks, as hinted at by the research undertaken by ITC economists, leaves a significant question mark hanging over the ability of nations worldwide to access and apply these critical healthcare provisions equally and without unnecessary delay.
For legal professionals grappling with the difficult issues surrounding intellectual property rights in a time of global crisis, gaining a more in-depth understanding of the ITC’s findings could be illuminating. The full details of the report by these economists at the U.S. International Trade Commission can be found here.